Imprimis Pharmaceuticals (IMMY) Upgraded by ValuEngine to Hold

Imprimis Pharmaceuticals (NASDAQ:IMMY) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Imprimis Pharmaceuticals stock remained flat at $$2.21 during midday trading on Wednesday. The company had a trading volume of 26,886 shares, compared to its average volume of 428,642. The company has a debt-to-equity ratio of 5.64, a current ratio of 1.53 and a quick ratio of 1.14. Imprimis Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $4.65.

How to Become a New Pot Stock Millionaire

Imprimis Pharmaceuticals (NASDAQ:IMMY) last announced its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter. The firm had revenue of $7.34 million during the quarter. Imprimis Pharmaceuticals had a negative net margin of 44.76% and a negative return on equity of 248.39%.

A hedge fund recently raised its stake in Imprimis Pharmaceuticals stock. Granite Investment Partners LLC grew its stake in shares of Imprimis Pharmaceuticals (NASDAQ:IMMY) by 46.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 186,214 shares of the specialty pharmaceutical company’s stock after purchasing an additional 59,000 shares during the quarter. Granite Investment Partners LLC owned approximately 0.91% of Imprimis Pharmaceuticals worth $316,000 as of its most recent SEC filing. Institutional investors own 10.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Imprimis Pharmaceuticals (IMMY) Upgraded by ValuEngine to Hold” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/18/imprimis-pharmaceuticals-immy-upgraded-by-valuengine-to-hold.html.

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals, Inc, an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. It offers ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply